Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX restores activity in the intrinsic pathway of the coagulation cascade. When administered, it binds to factor VIIIa on activated platelets, facilitating the conversion of factor X to Xa, which then generates thrombin. The resulting thrombin converts fibrinogen to fibrin, forming a stable clot and stopping bleeding.

The dose of Immunine is individualized for each patient. A qualified prescriber determines the amount based on the patient’s current factor IX activity level, body weight, severity of bleeding, and the clinical situation. No standard dosing regimen is provided publicly; dosing instructions are supplied on the prescription.

Safety data for Immunine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers must evaluate each case carefully and discuss potential risks with the patient.

To order Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain logistics if needed), and assists with import documentation.

Immunine is a plasma‑derived factor IX concentrate, whereas many alternatives are recombinant. Both provide functional factor IX, but recombinant products have a lower theoretical risk of viral transmission. Immunine may be preferred in settings where plasma‑derived products are standard or when specific regulatory approvals are required.

Immunine must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Immunine is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total volume are determined by the prescriber based on the patient’s factor IX level and clinical needs. Monitoring for infusion reactions is recommended during and after administration.

Serious risks include anaphylactic reactions, development of neutralizing antibodies (inhibitors) that reduce efficacy, thrombotic events such as deep‑vein thrombosis, and disseminated intravascular coagulation. Patients should be observed closely for signs of these events, and any suspected reaction should be reported immediately.

Immunine should not be used in individuals with known severe hypersensitivity to factor IX or any component of the formulation. Patients with a history of severe allergic reactions to plasma‑derived products should avoid it, and prescribers should assess risk before initiating therapy.